nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.04.2021 | Original Article

[¹⁸F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia

verfasst von: M. Rinzivillo, D. Prosperi, F. Mazzuca, L. Magi, E. Iannicelli, E. Pilozzi, G. Franchi, A. Laghi, B. Annibale, A. Signore, F. Panzuto

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to identify in patients with neuroendocrine neoplasia (NEN) the potential correlation between FDG-PET findings and responses to everolimus therapy to identify predictors of long-term efficacy.

Methods

Retrospective analysis of patients with sporadic, advanced, progressive NEN treated with everolimus was performed based on the available data on FDG-PET patients obtained before commencing therapy. Data are expressed as the median (25–75th IQR). Risk factor analysis and survival analysis were performed by logistic regression and Cox proportional hazard regression and the determination of Kaplan–Meier curves, as appropriate.

Results

Sixty-six patients were evaluated (NET G1 19.7%, NET G2 75.7%, and NET G3 4.6%), including 45.4% with positive FDG-PET findings. Overall, disease stabilization and a partial response were achieved for 71.2% and 6% of patients, respectively. A long-term response (> 24 months) was observed in 33% of patients. Ki67 was the only predictor of tumor progression (p = 0.03). No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings (median PFS was 24 months and 18 months, respectively, p = 0.337; the disease control rate was 83.3% and 70%, respectively, p = 0.245).

Conclusions

Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.

Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335–1342CrossRef

Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113(2):256–265CrossRef

Panzuto F, Merola E, Rinzivillo M et al (2014) Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 43(2):212–218CrossRef

Faggiano A, Ferolla P, Grimaldi F et al (2012) Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest 35(9):817–823. https://doi.org/10.3275/8102CrossRefPubMed

WHO classification of tumours of endocrine organs (2020) WHO classification of tumours, 4th edition, vol. 10, In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds) https://whobluebooks.iarc.fr; 978-92-832-4493-6

WHO classification of digestive system tumours (2020) WHO classification of tumours, 5th edition, vol. 1, https://whobluebooks.iarc.fr; 978-92-832-4499-8

WHO classification of tumours of lung, pleura, thymus and heart (2020) WHO classification of tumours, 4th edition, vol. 7, https://whobluebooks.iarc.fr; 978-92-832-4495-0

Cives M, Strosberg JR (2018) Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 68(6):471–487CrossRef

Bodei L, Ferone D, Grana CM et al (2009) Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 32:360–369CrossRef

10.

Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977CrossRef

11.

Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523CrossRef

12.

Lee L, Ito T, Jensen RT (2018) Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 18(9):837–860CrossRef

13.

de Mestier L, Armani M, Cros J et al (2019) Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. Dig Liver Dis 51:1720–1724CrossRef

14.

Bucau M, Laurent-Bellue A, Poté N et al (2018) 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation. Neuroendocrinology 106(3):274–282CrossRef

15.

Pavel M, O'Toole D, Costa F et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185CrossRef

16.

CTCAE (2020) CTCAE; Common terminology criteria for adverse events. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed April 2020

17.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRef

18.

Johnbeck CB, Munk Jensen M, Haagen Nielsen C et al (2014) 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice. PLoS ONE 9:e91387CrossRef

19.

Cejka D, Kuntner C, Preusser M et al (2009) FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br J Cancer 100(11):1739–1745CrossRef

20.

Lung MS, Hicks RJ, Pavlakis N et al (2020) The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸ F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia Pac J Clin Oncol. https://doi.org/10.1111/ajco.13307CrossRefPubMed

21.

Ito H, Kondo K, Kawahara T et al (2017) One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. Cancer Chemother Pharmacol 79(5):855–861CrossRef

22.

Chen JL, Appelbaum DE, Kocherginsky M et al (2013) FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med 2(4):545–552CrossRef

23.

Nogová L, Boellaard R, Kobe C et al (2009) Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 50(11):1815–1819CrossRef

24.

Sundin A, Arnold R, Baudin E et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological. Nuclear Med Hybrid Imaging Neuroendocrinol 105:212–244

25.

Partelli S, Rinzivillo M, Maurizi A et al (2014) The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology 100(4):293–299CrossRef

26.

Carideo L, Prosperi D, Panzuto F, et al (2019) Role of combined [⁶⁸Ga]Ga-DOTA-SST analogues and [¹⁸F]FDG PET/CT in the management of GEP-NENs: a systematic review. J Clin Med 8(7). pii: E1032.

27.

Chan DL, Pavlakis N, Schembri GP et al (2017) Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics 7(5):1149–1158CrossRef

28.

Seregni E, Ferrari L, Stivanello M et al (2000) Laboratory tests for neuroendocrine tumours. Q J Nucl Med 44(1):22–41PubMed

29.

Rinzivillo M, Partelli S, Prosperi D et al (2018) Clinical usefulness of ₁₈F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms. Oncologist 23(2):186–192CrossRef

30.

Zhang J, Liu Q, Singh A, et al (2020) Prognostic value of ₁₈F-FDG PET/CT in a large cohort of 495 patients with advanced metastatic neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT). J Nucl Med. pii: jnumed.119.241414.

31.

Severi S, Nanni O, Bodei L et al (2013) Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(6):881–888CrossRef

32.

Sansovini M, Severi S, Ianniello A et al (2017) Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ₁₇₇Lu-D OTATATE. Eur J Nucl Med Mol Imaging 44(3):490–499CrossRef

33.

Bongiovanni A, Recine F, Riva N et al (2017) Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of ₁₈FDG-PET/CT. Clin Lung Cancer 18(4):415–420CrossRef

34.

Panzuto F, Rinzivillo M, Fazio N et al (2014) Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 19(9):966–974CrossRef

35.

Faggiano A, Malandrino P, Modica R et al (2016) Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature. Oncologist 21(7):875–886. https://doi.org/10.1634/theoncologist.2015-0420CrossRefPubMedPubMedCentral

36.

Capdevila J, Teulé A, Barriuso J et al (2019) Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: The GETNE1003_EVERLAR study. Oncologist 24(1):38–46CrossRef

Titel: [18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia
verfasst von: M. Rinzivillo
D. Prosperi
F. Mazzuca
L. Magi
E. Iannicelli
E. Pilozzi
G. Franchi
A. Laghi
B. Annibale
A. Signore
F. Panzuto
Publikationsdatum: 01.04.2021
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 4/2021
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-020-01378-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

[¹⁸F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia